JPMorgan lifts Biogen rating as shares gain 2.1%

what happened

Biogen stock advanced 2.1% in Monday’s premarket session after JPMorgan moved its rating from Neutral to Overweight. The brokerage placed a $300 price target on the shares, representing a 33% increase from the previous close, according to Seeking Alpha and other media reports.

JPMorgan analyst Christopher Schott pointed to a stronger long-range growth outlook for the company. He said Biogen ranks among the more appealing names heading into 2027 as its business develops beyond reliance on Leqembi.

Earlier this month, Biogen reported that an experimental medicine produced sustained relief from skin manifestations in patients with an autoimmune condition during a mid-stage trial. At the same time, its established multiple sclerosis franchise is facing greater strain from pricing issues and competing treatments. The company is therefore depending on newer offerings, including the Alzheimer’s medicine Leqembi, to restore growth. SA Quant gives the stock a Hold rating (3.11), while Wall Street analysts retain a Buy view with an average score of 4.11. Seeking Alpha says its content is for informational purposes only and that it does not provide personal investment advice or operate as a licensed securities dealer, broker, US investment adviser, or investment bank.

why it matters

The upgrade highlights expectations for Biogen’s 2027 development pipeline, while pressure on its legacy multiple sclerosis portfolio leaves the company reliant on newer products to support expansion.

instruments